IP Library › Granted Patent US 12,486,289
Granted Patent B2
US 12,486,289 · App. 17/507,922 · Granted Dec 2, 2025

Tricyclic compounds as glycogen synthase kinase 3 (GSK3) inhibitors and uses thereof

Inventors: Florence Fevrier Wagner (Cambridge, MA); Michel Weiwer (Cambridge, MA); Arthur J. Campbell (Cambridge, MA); Joshua R. Sacher (Cambridge, MA); Edward Holson (Newton Highlands, MA); Brian Stuart Lucas (Arlington, MA); TeYu Chen (Cambridge, MA)
Assignees: The Broad Institute, Inc.; Biogen MA Inc.
C07D513/04A61K31/4745C07D498/04C07D513/20A61K45/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,486,289
App. No.
17/507,922
Granted
Dec 2, 2025
Kind
B2
Abstract

The present disclosure provides compounds of Formula (I), and salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs thereof. The provided compounds may be useful for inhibiting kinases, e.g., glycogen synthase kinase 3 (GSK3). The provided compounds may be able to selectively inhibit GSK3a, as compared to GSK3P and/or other kinases. The present disclosure further provides pharmaceutical compositions, kits, and methods of use, each of which involve the compounds. The compounds, pharmaceutical compositions, and kits may be useful for treating diseases associated with aberrant activity of GSK3a (e.g., Fragile X syndrome, attention deficit hyperactivity disorder (ADHD), childhood seizure, intellectual disability, diabetes, acute myeloid leukemia (AML), autism, and psychiatric disorder).

Claims (66)

1 . A method of therapeutically treating a disease in a subject in need thereof, the method comprising administering to the subject an effective amount of a compound of Formula (I):

or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, or isotopically labeled compound thereof, wherein:

the disease is diffuse Lewy body disease, Huntington's disease, spinal muscular atrophy, Wernicke-Korsakoff's related dementia, multiple sclerosis, neuroblastoma, neurofibroma, post-traumatic stress disorder, depression, or stroke;

X is —O— or —S—;

R 1 is substituted or unsubstituted C 1-12 alkyl, substituted or unsubstituted C 2-12 alkenyl, substituted or unsubstituted C 2-12 alkynyl, substituted or unsubstituted, 3- to 13-membered, monocyclic or bicyclic carbocyclyl, substituted or unsubstituted, 3- to 13-membered, monocyclic or bicyclic heterocyclyl, substituted or unsubstituted, 6- to 11-membered, monocyclic or bicyclic aryl, or substituted or unsubstituted, 5- to 11-membered, monocyclic or bicyclic heteroaryl;

R 2 is substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkonyl, substituted or unsubstituted C 2-6 alkynyl, substituted or unsubstituted, 3- to 7-membered, monocyclic carbocyclyl, or substituted or unsubstituted phenyl;

or R 1 and R 2 are joined to form substituted or unsubstituted, 3- to 13-membered, monocyclic or bicyclic carbocyclyl, or substituted or unsubstituted, 3- to 13-membered, monocyclic or bicyclic heterocyclyl;

each one of R 4a and R 4b is independently hydrogen, halogen, —CN, —OR A , —SR A , —N(R A ) 2 , substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, or substituted or unsubstituted C 2-6 alkynyl; or R 4a and R 4b are joined to form substituted or unsubstituted C 1-6 alkenyl, substituted or unsubstituted, 3- to 7-membered, monocyclic carbocyclyl, or substituted or unsubstituted, 3- to 7-membered, monocyclic heterocyclyl;

each one of R 5a and R 5b is independently hydrogen, halogen, —CN, —OR A , —SR A , —N(R A ) 2 , substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, or substituted or unsubstituted C 2-6 alkynyl; or R 5a and R 5b are joined to form substituted or unsubstituted C 1-6 alkenyl, substituted or unsubstituted, 3- to 7-membered, monocyclic carbocyclyl, or substituted or unsubstituted, 3- to 7-membered, monocyclic heterocyclyl;

each one of R 6a and R 6b is independently hydrogen, halogen, —CN, —OR A , —SR A , —N(R A ) 2 , substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, or substituted or unsubstituted C 2-6 alkynyl; or R 6a and R 6b are joined to form substituted or unsubstituted C 1-6 alkenyl, substituted or unsubstituted, 3- to 7-membered, monocyclic carbocyclyl, or substituted or unsubstituted, 3- to 7-membered, monocyclic heterocyclyl;

R 8 is hydrogen, halogen, —CN, —OR A , —SR A , —N(R A ) 2 , substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl, or substituted or unsubstituted, 3- to 5-membered, monocyclic carbocyclyl;

each R A is independently hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl, substituted or unsubstituted, 3- to 7-membered, monocyclic carbocyclyl, substituted or unsubstituted, 3- to 7-membered, monocyclic heterocyclyl, substituted or unsubstituted phenyl, substituted or unsubstituted, 5- or 6-membered, monocyclic heteroaryl, an oxygen protecting group when attached to an oxygen atom, a sulfur protecting group when attached to a sulfur atom, or a nitrogen protecting group when attached to a nitrogen atom; or two R A attached to the same nitrogen atom are joined to form substituted or unsubstituted, 3- to 7-membered, monocyclic heterocyclyl, or substituted or unsubstituted, 5- or 6-membered, monocyclic heteroaryl;

each instance of the heterocyclyl comprises in the heterocyclic ring system one, two, three, or four heteroatoms independently selected from the group consisting of oxygen, nitrogen, and sulfur, as valency permits;

each instance of the heteroaryl comprises in the heteroaryl ring system one, two, three, or four heteroatoms independently selected from the group consisting of oxygen, nitrogen, and sulfur, as valency permits; and

the effective amount is effective for treating the disease.

2 . The method of claim 1 comprising administering to the subject an effective amount of the compound, or a pharmaceutically acceptable salt or tautomer thereof.

3 . The method of claim 1 , wherein X is —S—.

4 . The method of claim 1 , wherein R 1 is substituted or unsubstituted phenyl.

5 . The method of claim 1 , wherein R 2 is substituted or unsubstituted C 1-6 alkyl.

6 . The method of claim 1 , wherein R 2 is —CH 3 or —C 2 H 5 .

7 . The method of claim 1 , wherein the compound is of the formula:

or a pharmaceutically acceptable salt or tautomer thereof, wherein:

Ring B is substituted or unsubstituted, 3- to 7-membered, monocyclic carbocyclyl, or substituted or unsubstituted, 3- to 7-membered, monocyclic heterocyclyl;

each instance of R 7 is independently hydrogen, halogen, substituted or unsubstituted C 1-12 alkyl, substituted or unsubstituted C 2-12 alkenyl, substituted or unsubstituted C 2-12 alkynyl, substituted or unsubstituted, 3- to 13-membered, monocyclic or bicyclic carbocyclyl, substituted or unsubstituted, 3- to 13-membered, monocyclic or bicyclic heterocyclyl, substituted or unsubstituted, 6- to 11-membered, monocyclic or bicyclic aryl, substituted or unsubstituted, 5- to 11-membered, monocyclic or bicyclic heteroaryl, —OR A , —N(R A ) 2 , —SR A , —CN, —SCN, —C(═O)R A , —C(═O)OR A , —C(═O)N(R A ) 2 , —C(═NR A )R A , —C(═NR A )OR A , —C(═NR A )N(R A ) 2 , —NO 2 , —N 3 , —NR A C(═O)R A , —NR A C(═O)OR A , —NR A C(═O)N(R A ) 2 , —NR A C(═NR A )R A , —NR A C(═NR A )OR A , —NR A C(═NR A )N(R A ) 2 , —OC(═O)R A , —OC(═O)OR A , —OC(═O)N(R A ) 2 , —OC(═NR A )R A , —OC(═NR A )OR A , —OC(═NR A )N(R A ) 2 , —NR A S(═O) 2 R A , —NR A S(═O),OR A , —NR A S(═O) 2 N(R A ) 2 , —OS(═O) 2 R A , —OS(═O) 2 OR A , —OS(═O) 2 N(R A ) 2 , —S(═O) 2 R A , —S(═O) 2 OR A , or —S(═O) 2 N(R A ) 2 ; or

two R 7 groups are joined to form substituted or unsubstituted, 3- to 7-membered, monocyclic carbocyclyl, substituted or unsubstituted, 3- to 7-membered, monocyclic heterocyclyl, substituted or unsubstituted phenyl, or substituted or unsubstituted, 5- or 6-membered, monocyclic heteroaryl; and

q is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12, as valency permits.

8 . The method of claim 1 , wherein the compound is of the formula:

or a pharmaceutically acceptable salt or tautomer thereof, wherein:

Ring B is substituted or unsubstituted, 3- to 7-membered, monocyclic carbocyclyl, or substituted or unsubstituted, 3- to 7-membered, monocyclic heterocyclyl;

each instance of R 7 is independently hydrogen, halogen, substituted or unsubstituted C 1-12 alkyl, substituted or unsubstituted C 2-12 alkenyl, substituted or unsubstituted C 2-12 alkynyl, substituted or unsubstituted, 3- to 13-membered, monocyclic or bicyclic carbocyclyl, substituted or unsubstituted, 3- to 13-membered, monocyclic or bicyclic heterocyclyl, substituted or unsubstituted, 6- to 11-membered, monocyclic or bicyclic aryl, substituted or unsubstituted, 5- to 11-membered, monocyclic or bicyclic heteroaryl, —OR A , —N(R A ) 2 , —SR A , —CN, —SCN, —C(═O)R A , —C(═O)OR A , —C(═O)N(R A ) 2 , —C(═NR A )R A , —C(═NR A )OR A , —C(═NR A )N(R A ) 2 , —NO 2 , —N 3 , —NR A C(═O)R A , —NR A C(═O)OR A , —NR A C(═O)N(R A ) 2 , —NR A C(═NR A )R A , —NR A C(═NR A )OR A , —NR A C(═NR A )N(R A ) 2 , —OC(═O)R A , —OC(═O)OR A , —OC(═O)N(R A ) 2 , —OC(═NR A )R A , —OC(═NR A )OR A , —OC(═NR A )N(R A ) 2 , —NR A S(═O) 2 R A , —NR A S(═O) 2 OR A , —NR A S(═O) 2 N(R A ) 2 , —OS(═O) 2 R A , —OS(═O) 2 OR A , —OS(═O) 2 N(R A ) 2 , —S(═O) 2 R A , —S(═O) 2 OR A , or —S(═O) 2 N(R A ) 2 ; or

two R 7 groups on the same carbon atom are joined to form substituted or unsubstituted C 1-6 alkenyl; and

q is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12, as valency permits.

9 . The method of claim 1 , wherein the compound is of the formula:

or a pharmaceutically acceptable salt or tautomer thereof, wherein:

Ring A is substituted or unsubstituted, 5- to 6-membered, monocyclic heteroaryl;

Ring B is substituted or unsubstituted, 3- to 7-membered, monocyclic carbocyclyl, or substituted or unsubstituted, 3- to 7-membered, monocyclic heterocyclyl;

Y is C or N;

Z is C or N;

is a single or double bond, as valency permits;

each instance of R 7 is independently hydrogen, halogen, substituted or unsubstituted C 1-12 alkyl, substituted or unsubstituted C 2-12 alkenyl, substituted or unsubstituted C 2-12 alkynyl, substituted or unsubstituted, 3- to 13-membered, monocyclic or bicyclic carbocyclyl, substituted or unsubstituted, 3- to 13-membered, monocyclic or bicyclic heterocyclyl, substituted or unsubstituted, 6- to 11-membered, monocyclic or bicyclic aryl, substituted or unsubstituted, 5- to 11-membered, monocyclic or bicyclic heteroaryl, OR A , —N(R) 2 , —SR A , —CN, —SCN, —C(═O)R A , —C(═O)OR A , —C(═O)N(R A ) 2 , —C(═NR A )R A , —C(═NR A )OR A , —C(═NR A )N(R A ) 2 , —NO 2 , —N 3 , —NR A C(═O)R A , —NR A C(═O)OR A , —NR A C(═O)N(R A ) 2 , —NR A C(═NR A )R A , —NR A C(═NR A )OR A , —NR A C(═NR A )N(R A ) 2 , OC(═O)R A , —OC(═O)OR A , —OC(═O)N(R A ) 2 , —OC(═NR A )R A , —OC(═NR A )OR A , —OC(═NR A )N(R A ) 2 , —NR A S(═O) 2 R A , —NR A S(═O) 2 OR A , —NR A S(═O) 2 N(R A ) 2 , —OS(═O) 2 R A , —OS(═O) 2 OR A , —OS(═O) 2 N(R A ) 2 , —S(═O) 2 R A , —S(═O) 2 OR A , or —S(═O) 2 N(R A ) 2 ; or

two R 7 groups on the same carbon atom are joined to form substituted or unsubstituted C 1-6 alkenyl; and

q is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12, as valency permits.

10 . The method of claim 1 , wherein each one of R 4a and R 4b is hydrogen.

11 . The method of claim 1 , wherein R 4a is substituted or unsubstituted C 1-6 alkyl, and R 4b is hydrogen; or each one of R 4a and R 4b is substituted or unsubstituted C 1-6 alkyl.

12 . The method of claim 1 , wherein each one of R 5a and R 5b is substituted or unsubstituted C 1-6 alkyl.

13 . The method of claim 1 , wherein each one of R 5a and R 5b is hydrogen; or R 5a is substituted or unsubstituted C 1-6 alkyl, and R 5b is hydrogen.

14 . The method of claim 1 , wherein each one of R 5a and R 5b is —CH 3 .

15 . The method of claim 1 , wherein each one of R 6a and R 6b is hydrogen.

16 . The method of claim 1 , wherein R 6a is substituted or unsubstituted C 1-6 alkyl, and R 6b is hydrogen; or each one of R 6a and R 6b is substituted or unsubstituted C 1-6 alkyl.

17 . The method of claim 1 , wherein R 8 is hydrogen.

18 . The method of claim 1 , wherein the compound is of the formula:

or a pharmaceutically acceptable salt or tautomer thereof.

19 . The method of claim 1 , wherein the compound is of the formula:

or a pharmaceutically acceptable salt or tautomer thereof.

20 . The method of claim 1 , wherein the disease is post-traumatic stress disorder or depression.

21 . The method of claim 1 , wherein the disease is diffuse Lewy body disease, Huntington's disease, spinal muscular atrophy, Wernicke-Korsakoff's related dementia, or multiple sclerosis.

22 . The method of claim 1 , wherein the disease is neuroblastoma or neurofibroma.

23 . The method of claim 7 , wherein the disease is post-traumatic stress disorder or depression.

24 . The method of claim 7 , wherein the disease is diffuse Lewy body disease, Huntington's disease, spinal muscular atrophy, Wernicke-Korsakoff's related dementia, or multiple sclerosis.

25 . The method of claim 7 , wherein the disease is neuroblastoma or neurofibroma.

26 . The method of claim 8 , wherein the disease is post-traumatic stress disorder or depression.

27 . The method of claim 8 , wherein the disease is diffuse Lewy body disease, Huntington's disease, spinal muscular atrophy, Wernicke-Korsakoff's related dementia, or multiple sclerosis.

28 . The method of claim 8 , wherein the disease is neuroblastoma or neurofibroma.

29 . The method of claim 9 , wherein the disease is post-traumatic stress disorder or depression.

30 . The method of claim 9 , wherein the disease is diffuse Lewy body disease, Huntington's disease, spinal muscular atrophy, Wernicke-Korsakoff's related dementia, or multiple sclerosis.

31 . The method of claim 9 , wherein the disease is neuroblastoma or neurofibroma.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 31, 2022
From: LUCAS, BRIAN STUART; CHEN, TEYU
To: BIOGEN MA INC.
Reel/Frame 058831/0666 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 31, 2022
From: WAGNER, FLORENCE FEVRIER; WEIWER, MICHEL; CAMPBELL, ARTHUR J.; SACHER, JOSHUA R.; HOLSON, EDWARD
To: THE BROAD INSTITUTE, INC.
Reel/Frame 058907/0292 →
Continuity (3)
Continuation 16603112
Provisional Application 62481981 · Apr 5, 2017
Related Publication 20220112216A1 · Apr 14, 2022
References Cited (186)
US 4270537A · Romaine · 1981 [cited by applicant]
US 4596556A · Morrow et al. · 1986 [cited by applicant]
US 4790824A · Morrow et al. · 1988 [cited by applicant]
US 4886499A · Cirelli et al. · 1989 [cited by applicant]
US 4940460A · Casey et al. · 1990 [cited by applicant]
US 4941880A · Burns · 1990 [cited by applicant]
US 5015235A · Crossman · 1991 [cited by applicant]
US 5064413A · McKinnon et al. · 1991 [cited by applicant]
US 5141496A · Dalto et al. · 1992 [cited by applicant]
US 5190521A · Hubbard et al. · 1993 [cited by applicant]
US 5312335A · McKinnon et al. · 1994 [cited by applicant]
US 5328483A · Jacoby · 1994 [cited by applicant]
US 5334114A · Ando et al. · 1994 [cited by applicant]
US 5339163A · Homma et al. · 1994 [cited by applicant]
US 5383851A · McKinnon et al. · 1995 [cited by applicant]
US 5417662A · Hjertman et al. · 1995 [cited by applicant]
US 5466220A · Brenneman · 1995 [cited by applicant]
US 5480381A · Weston · 1996 [cited by applicant]
US 5503627A · McKinnon et al. · 1996 [cited by applicant]
US 5520639A · Peterson et al. · 1996 [cited by applicant]
US 5527288A · Gross et al. · 1996 [cited by applicant]
US 5569189A · Parsons · 1996 [cited by applicant]
US 5599302A · Lilley et al. · 1997 [cited by applicant]
US 5649912A · Peterson · 1997 [cited by applicant]
US 5704911A · Parsons · 1998 [cited by applicant]
US 5750528A · Brown et al. · 1998 [cited by applicant]
US 5893397A · Peterson et al. · 1999 [cited by applicant]
US 5993412A · Deily et al. · 1999 [cited by applicant]
US 6977262B2 · Kohara et al. · 2005 [cited by applicant]
US 7067507B2 · Pulley · 2006 [cited by examiner]
US 8778986B1 · Tan et al. · 2014 [cited by applicant]
US 9096594B2 · Wagner et al. · 2015 [cited by applicant]
US 10137122B2 · Wagner et al. · 2018 [cited by applicant]
US 11052080B2 · Wagner et al. · 2021 [cited by applicant]
US 11203601B2 · Wagner et al. · 2021 [cited by applicant]
US 20040052822A1 · Kohara et al. · 2004 [cited by applicant]
US 20080051394A1 · Schiemann et al. · 2008 [cited by applicant]
US 20090181986A1 · Abelman et al. · 2009 [cited by applicant]
US 20110008468A1 · Haggarty et al. · 2011 [cited by applicant]
US 20140107141A1 · Wagner et al. · 2014 [cited by applicant]
US 20150307516A1 · Lee et al. · 2015 [cited by applicant]
US 20150313890A1 · Wagner et al. · 2015 [cited by applicant]
US 20160375006A1 · Scolnick et al. · 2016 [cited by applicant]
US 20190175584A1 · Wagner et al. · 2019 [cited by applicant]
US 20200109154A1 · Wagner et al. · 2020 [cited by applicant]
US 20220160702A1 · Wagner et al. · 2022 [cited by applicant]
DE 2722416A1 · 1978 [cited by applicant]
JP 2005501800A · 2005 [cited by applicant]
JP 2009501778A · 2009 [cited by applicant]
WO WO9424131A1 · 1994 [cited by applicant]
WO WO0032606A1 · 2000 [cited by applicant]
WO WO02062795A2 · 2002 [cited by applicant]
WO WO2007012972A2 · 2007 [cited by applicant]
WO WO2008016123A1 · 2008 [cited by applicant]
WO WO2010133794A1 · 2010 [cited by applicant]
WO WO2013007663A1 · 2013 [cited by applicant]
WO WO2014003098A1 · 2014 [cited by applicant]
WO WO2014059383A1 · 2014 [cited by applicant]
WO WO2015087996A1 · 2015 [cited by applicant]
WO WO2016037026A1 · 2016 [cited by applicant]
Zawilska. Pharmacological Reports, 2013, 65, 1-14 (Year: 2013). [cited by examiner]
Aricioglu. Bulletin of Clinical Pharmacology, 2014, 24(1), 97-108 (Year: 2014). [cited by examiner]
Tandon. Schizophrenia Research, 2010, 122, 1-23 (Year: 2010). [cited by examiner]
Forde. Cellular and Molecular Life Sciences, 2007, 64, 1930-1944 (Year: 2007). [cited by examiner]
DICKEY. Journal of Neurooncology, 2011, 104, 145-153 (Year: 2011). [cited by examiner]
International Search Report and Written Opinion for PCT/US2013/064716, mailed Nov. 19, 2013. [cited by applicant]
International Preliminary Report on Patentability for PCT/US2013/064716, mailed Apr. 23, 2015. [cited by applicant]
Extended European Search Report for Application No. 18781394.4, mailed Nov. 19, 2020. [cited by applicant]
Invitation to Pay Additional Fees for PCT/US2018/26339, mailed May 31, 2018. [cited by applicant]
International Search Report and Written Opinion for PCT/US2018/26339, mailed Jul. 20, 2018. [cited by applicant]
International Preliminary Report on Patentability for PCT/US2018/26339, mailed Oct. 17, 2019. [cited by applicant]
[No Author Listed] American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. Arlington, VA, American Psychiatric Association, 2013. pp. 33-41, 809-816. [cited by applicant]
Achab et al., A short route to functionalized imidazo[4,5-c]carbazoles. Synthesis of the first example of the imidazo[4,5-c]β-carboline ring system. Tetrahedron Letters. Dec. 10, 2001;42(50):8825-28. [cited by applicant]
An et al., Discovery of Potent and Highly Selective Inhibitors of GSK3b. Received on Apr. 16, 2012. Released in excerpt form on May 7, 2013. [Last Update: May 13, 2014]. Full report published on Jul. 17, 2014. In: Probe… [cited by applicant]
Banerji et al., The intersection of genetic and chemical genomic screens identifies GSK-3α as a target in human acute myeloid leukemia. J Clin Invest. Mar. 1, 2012;122(3):935-47. doi: 10.1172/JCI46465. Epub Feb. 13, 201… [cited by applicant]
Bang et al., GSK-3α promotes oncogenic KRAS function in pancreatic cancer via TAK1-TAB stabilization and regulation of noncanonical NF-κB. Cancer Discov. Jun. 2013;3(6):690-703. doi: 10.1158/2159-8290.CD-12-0541. Epub A… [cited by applicant]
Barnes et al., Convergence of Hippocampal Pathophysiology in Syngap+/− and Fmr1−/y Mice. J Neurosci. Nov. 11, 2015;35(45):15073-81. doi: 10.1523/JNEUROSCI.1087-15.2015. [cited by applicant]
Beaulieu et al., The Akt-GSK-3 signaling cascade in the actions of dopamine. Trends Pharmacol Sci. Apr. 2007;28(4):166-72. Epub Mar. 8, 2007. Review. [cited by applicant]
Beaulieu et al., Lithium antagonizes dopamine-dependent behaviors mediated by an AKT/glycogen synthase kinase 3 signaling cascade. Proc Natl Acad Sci U S A. Apr. 6, 2004;101(14):5099-104. doi: 10.1073/pnas.0307921101. E… [cited by applicant]
Beurel et al., Inhibition of glycogen synthase kinase-3 is necessary for the rapid antidepressant effect of ketamine in mice. Mol Psychiatry. Nov. 2011;16(11):1068-70. doi: 10.1038/mp.2011.47. Epub Apr. 19, 2011. [cited by applicant]
Biechele et al., Assaying beta-catenin/TCF transcription with beta-catenin/TCF transcription-based reporter constructs. Methods Mol Biol. 2008;468:99-110. doi: 10.1007/978-1-59745-249-6_8. [cited by applicant]
Chalecka-Franaszek et al., Lithium activates the serine/threonine kinase Akt-1 and suppresses glutamate-induced inhibition of Akt-1 activity in neurons. Proc Natl Acad Sci U S A. Jul. 20, 1999;96(15):8745-50. [cited by applicant]
Chang et al., Synthesis and application of functionally diverse 2,6,9-trisubstituted purine libraries as CDK inhibitors. Chem Biol. Jun. 1999;6(6):361-75. [cited by applicant]
Cheong et al., Phosphatase and tensin homologue phosphorylation in the C-terminal regulatory domain is frequently observed in acute myeloid leukaemia and associated with poor clinical outcome. Br J Haematol. Aug. 2003;1… [cited by applicant]
Cozza et al., Identification of novel protein kinase CK1 delta (CK1delta) inhibitors through structure-based virtual screening. [cited by applicant]
Dahlhoff et al., AKT/GSK-3beta/beta-catenin signalling within hippocampus and amygdala reflects genetically determined differences in posttraumatic stress disorder like symptoms. Neuroscience. Sep. 1, 2010;169(3):1216-2… [cited by applicant]
De Sarno et al., Regulation of Akt and glycogen synthase kinase-3 beta phosphorylation by sodium valproate and lithium. Neuropharmacology. Dec. 2002;43(7):1158-64. [cited by applicant]
Dirzin et al., Structure-Activity studies for a novel series of tricyclic dihydropyrimidines as K(ATP) channel openers (KCOs). Bioorg Med Chem Lett. Jun. 3, 2002;12(11):1481-4. [cited by applicant]
Doble et al., Functional redundancy of GSK-3alpha and GSK-3beta in Wnt/beta-catenin signaling shown by using an allelic series of embryonic stem cell lines. Dev Cell. Jun. 2007;12(6):957-71. [cited by applicant]
Emamian et al., Convergent evidence for impaired AKT1-GSK3beta signaling in schizophrenia. Nat Genet. Feb. 2004;36(2):131-7. Epub Jan. 25, 2004. [cited by applicant]
Emamian, AKT/GSK3 signaling pathway and schizophrenia. Front Mol Neurosci. Mar. 15, 2012;5:33. doi: 10.3389/fnmol.2012.00033. eCollection 2012. [cited by applicant]
Forde et al., Glycogen synthase kinase 3: a key regulator of cellular fate. Cell Mol Life Sci. Aug. 2007;64(15):1930-44. Review. [cited by applicant]
Foucourt et al., Design and synthesis of thiazolo[5,4-f]quinazolines as DYRK1A inhibitors, part I. Molecules. Sep. 29, 2014;19(10):15546-71. doi: 10.3390/molecules191015546. [cited by applicant]
Franklin et al., Glycogen synthase kinase-3 inhibitors reverse deficits in long-term potentiation and cognition in fragile X mice. Biol Psychiatry. Feb. 1, 2014;75(3):198-206. doi: 10.1016/j.biopsych.2013.08.003. Epub S… [cited by applicant]
Georgievska et al., AZD1080, a novel GSK3 inhibitor, rescues synaptic plasticity deficits in rodent brain and exhibits peripheral target engagement in humans. J Neurochem. May 2013; 125(3):446-56. doi: 10.1111/jnc.12203. [cited by applicant]
Gould et al., Targeting glycogen synthase kinase-3 in the CNS: implications for the development of new treatments for mood disorders. Curr Drug Targets. Nov. 2006;7(11):1399-409. Review. [cited by applicant]
Hahn et al., Proteomic and genetic approaches identify Syk as an AML target. Cancer Cell. Oct. 6, 2009;16(4):281-94. doi: 10.1016/j.ccr.2009.08.018. [cited by applicant]
Harris, Intellectual Disability: A Guide for Families and Professionals. Oxford University Press, 2010. pp. 51-53, 65. [cited by applicant]
Hinze et al., Synthetic Lethality of Wnt Pathway Activation and Asparaginase in Drug-Resistant Acute Leukemias. Cancer Cell. Apr. 15, 2019;35(4):664-676.e7. doi: 10.1016/j.ccell.2019.03.004. [cited by applicant]
Hooper et al., The GSK3 hypothesis of Alzheimer's disease. J Neurochem. Mar. 2008;104(6):1433-9. Epub Dec. 18, 2007. Review. [cited by applicant]
Jones et al., Animal models of schizophrenia. [cited by applicant]
Kaidanovich-Beilin et al., Abnormalities in brain structure and behavior in GSK-3alpha mutant mice. Mol Brain. Nov. 19, 2009;2:35. doi: 10.1186/1756-6606-2-35. [cited by applicant]
Kelleher et al., The autistic neuron: troubled translation? Cell. Oct. 31, 2008;135(3):401-6. doi: 10.1016/j.cell.2008.10.017. [cited by applicant]
Koh et al., Inhibition of glycogen synthase kinase-3 suppresses the onset of symptoms and disease progression of G93A-SOD1 mouse model of ALS. Exp Neurol. Jun. 2007;205(2):336-46. Epub Mar. 12, 2007. [cited by applicant]
Kozlovsky et al., Reduced GSK-3beta mRNA levels in postmortem dorsolateral prefrontal cortex of schizophrenic patients. J Neural Transm. Dec. 2004;111(12):1583-92. Epub Jun. 30, 2004. [cited by applicant]
Leclerc et al., Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inh… [cited by applicant]
Lee et al., Developing therapeutic approaches to tau, selected kinases, and related neuronal protein targets. Cold Spring Harb Perspect Med. Sep. 2011;1(1):a006437. doi:10.1101/cshperspect.a006437. Review. [cited by applicant]
Lee et al., Solid-phase synthesis of thiazolo[4,5-b]pyridine derivatives using Friedländer reaction. J Comb Chem. Jan.-Feb. 2010;12(1):95-9. doi: 10.1021/cc900147y. [cited by applicant]
Lei et al., GSK-3 in Neurodegenerative Diseases. Int J Alzheimers Dis. 2011;2011:189246, 9 pages. doi: 10.4061/2011/189246. Epub May 4, 2011. [cited by applicant]
Leost et al., Paullones are potent inhibitors of glycogen synthase kinase-3beta and cyclin-dependent kinase 5/p25. Eur J Biochem. Oct. 2000;267(19):5983-94. [cited by applicant]
Li et al., Lithium chloride suppresses colorectal cancer cell survival and proliferation through ROS/GSK-3B/NF-KB signaling pathway. Oxid Med Cell Longev. 2014;2014:241864. doi: 10.1155/2014/241864. Epub Jun. 5, 2014. [cited by applicant]
Lo Monte et al., Identification of glycogen synthase kinase-3 inhibitors with a selective sting for glycogen synthase kinase-3x. J Med Chem. May 10, 2012;55(9):4407-24. doi: 10.1021/jm300309a. Epub May 1, 2012. [cited by applicant]
Macaulay et al., Glycogen synthase kinase 3alpha-specific regulation of murine hepatic glycogen metabolism. Cell Metab. Oct. 2007;6(4):329-37. [cited by applicant]
Manisastry et al., Early temporal-specific responses and differential sensitivity to lithium and Wnt-3A exposure during heart development. Dev Dyn. Aug. 2006;235(8):2160-74. [cited by applicant]
Manoukian et al., Role of glycogen synthase kinase-3 in cancer: regulation by Wnts and other signaling pathways. Adv Cancer Res. 2002;84:203-29. Review. [cited by applicant]
Mao et al., Disrupted in schizophrenia 1 regulates neuronal progenitor proliferation via modulation of GSK3beta/beta-catenin signaling. Cell. Mar. 20, 2009;136(6):1017-31. doi:10.1016/j.cell.2008.12.044. [cited by applicant]
Matsuda et al., Distinct roles of GSK-3alpha and GSK-3beta phosphorylation in the heart under pressure overload. Proc Natl Acad Sci U S A. Dec. 30, 2008;105(52):20900-5. doi: 10.1073/pnas.0808315106. Epub Dec. 23, 2008. [cited by applicant]
Mayeku et al., Thalictramine, a new alkaloid from Thalictrum rhyncocarpum (Dill & Rich) and its anti-bacterial activity. Journal of Chemical and Pharmaceutical Research. Dec. 31, 2014; 6(11):1-5. [cited by applicant]
Meijer et al., GSK-3-selective inhibitors derived from Tyrian purple indirubins. Chem Biol. Dec. 2003;10(12):1255-66. [cited by applicant]
Meijer et al., Inhibition of cyclin-dependent kinases, GSK-3beta and CK1 by hymenialdisine, a marine sponge constituent. Chem Biol. Jan. 2000;7(1):51-63. [cited by applicant]
Min et al., Elevated glycogen synthase kinase-3 activity in Fragile X mice: key metabolic regulator with evidence for treatment potential. Neuropharmacology. Feb. 2009;56(2):463-72. doi: 10.1016/j.neuropharm.2008.09.017… [cited by applicant]
Mines et al., GSK3 influences social preference and anxiety-related behaviors during social interaction in a mouse model of fragile X syndrome and autism. PLoS One. Mar. 16, 2010;5(3):e9706, 12 pages. doi: 10.1371/journ… [cited by applicant]
Mukai et al., Molecular substrates of altered axonal growth and brain connectivity in a mouse model of schizophrenia. Neuron. May 6, 2015;86(3):680-95. doi: 10.1016/j.neuron.2015.04.003. [cited by applicant]
Neumann et al., Evaluation of Improved Glycogen Synthase Kinase-3α Inhibitors in Models of Acute Myeloid Leukemia. J Med Chem. Nov. 25, 2015;58(22):8907-19. doi: 10.1021/acs.jmedchem.5b01200. [cited by applicant]
Norton et al. Association analysis of AKT1 and schizophrenia in a UK case control sample. Schizophr Res. Jul. 2007;93(1-3):58-65. Epub Mar. 26, 2007. [cited by applicant]
Pan et al., AKT kinase activity is required for lithium to modulate mood-related behaviors in mice. Neuropsychopharmacology. Jun. 2011;36(7):1397-411. doi: 10.1038/npp.2011.24. Epub Mar. 9, 2011. [cited by applicant]
Phiel et al., GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides. Nature. May 22, 2003;423(6938):435-9. [cited by applicant]
Piazza et al., Glycogen Synthase Kinase-3 regulates multiple myeloma cell growth and bortezomib-induced cell death. BMC Cancer. Oct. 4, 2010;10:526. doi: 10.1186/1471-2407-10-526. [cited by applicant]
Polter et al., Deficiency in the inhibitory serine-phosphorylation of glycogen synthase kinase-3 increases sensitivity to mood disturbances. Neuropsychopharmacology. Jul. 2010;35(8):1761-74. doi: 10.1038/npp.2010.43. Ep… [cited by applicant]
Polychronopoulos et al., Structural basis for the synthesis of indirubins as potent and selective inhibitors of glycogen synthase kinase-3 and cyclin-dependent kinases. J Med Chem. Feb. 12, 2004;47(4):935-46. [cited by applicant]
Portis et al., The role of glycogen synthase kinase-3 signaling in neurodevelopment and fragile X syndrome. Int J Physiol Pathophysiol Pharmacol. 2012;4(3):140-8. Epub Sep 20, 2012. [cited by applicant]
Quiroga et al., An efficient synthesis of pyrazolo[3,4-b]pyridine-4-spiroindolinones by a three-component reaction of 5-aminopyrazoles, isatin, and cyclic β-diketones. Tetrahedron Letters. 2011;52(21):2664-6. [cited by applicant]
Quiroga et al., Regioselective synthesis of 4,7,8,9-tetrahydro-2H-pyrazolo[3,4-b]quinolin-5(6H)-ones. Mechanism and structural analysis. Tetrahedron. 2001;57(32):6947-53. [cited by applicant]
Robinson. Protein -RNA interaction links fragile X syndrome and Alzheimer disease. PLoS Biology. 2007;(5)e84. [cited by applicant]
Rowe et al., GSK-3 is a viable potential target for therapeutic intervention in bipolar disorder. Neurosci Biobehav Rev. 2007;31(6):920-31. Epub Mar. 15, 2007. [cited by applicant]
Ryves et al., Lithium inhibits glycogen synthase kinase-3 by competition for magnesium. Biochem Biophys Res Commun. Jan. 26, 2001;280(3):720-5. [cited by applicant]
Song et al., Central role of glycogen synthase kinase-3beta in endoplasmic reticulum stress-induced caspase-3 activation. J Biol Chem. Nov. 22, 2002;277(47):44701-8. Epub Sep. 12, 2002. [cited by applicant]
Stegmaier et al., Gene expression-based high-throughput screening(GE-HTS) and application to leukemia differentiation. Nat Genet. Mar. 2004;36(3):257-63. Epub Feb. 8, 2004. [cited by applicant]
Thiselton et al., AKT1 is associated with schizophrenia across multiple symptom dimensions in the Irish study of high density schizophrenia families. Biol Psychiatry. Mar. 1, 2008;63(5):449-57. Epub Sep. 6, 2007. [cited by applicant]
Wada, GSK-3 inhibitors and insulin receptor signaling in health, disease, and therapeutics. Front Biosci (Landmark Ed). Jan. 1, 2009;14:1558-70. Review. [cited by applicant]
Wagman et al., Discovery and development of GSK3 inhibitors for the treatment of type 2 diabetes. Curr Pharm Des. 2004;10(10):1105-37. Review. [cited by applicant]
Wagner et al., Inhibitors of Glycogen Synthase Kinase 3 with Exquisite Kinome-Wide Selectivity and Their Functional Effects. ACS Chem Biol. Jul. 15, 2016;11(7):1952-63. doi: 10.1021/acschembio.6b00306. Epub May 13, 2016. [cited by applicant]
Walpita et al., A human islet cell culture system for high-throughput screening. J Biomol Screen. Apr. 2012;17(4):509-18. doi: 10.1177/1087057111430253. [cited by applicant]
Wang et al., Changes of tau profiles in brains of the hamsters infected with scrapie strains 263 K or 139 A possibly associated with the alteration of phosphate kinases. BMC Infect Dis. Apr. 1, 2010;10:86, 10 pages. doi… [cited by applicant]
Wang et al., Downregulation of Mcl-1 through GSK-3β activation contributes to arsenic trioxide-induced apoptosis in acute myeloid leukemia cells. Leukemia. Feb. 2013;27(2):315-24. doi: 10.1038/leu.2012.180. Epub Jul. 3,… [cited by applicant]
Wang et al., Glycogen synthase kinase 3 in MLL leukaemia maintenance and targeted therapy. Nature. Oct. 30, 2008;455(7217):1205-9. doi: 10.1038/nature07284. Epub Sep. 17, 2008. [cited by applicant]
Wang et al., GSK-3 promotes conditional association of CREB and its coactivators with MEIS1 to facilitate HOX-mediated transcription and oncogenesis. Cancer Cell. Jun. 15, 2010;17(6):597-608. doi: 10.1016/j.ccr.2010.04.… [cited by applicant]
Wang et al., The Wnt/beta-catenin pathway is required for the development of leukemia stem cells in AML. Science. Mar. 26, 2010;327(5973):1650-3. doi: 10.1126/science.1186624. [cited by applicant]
Wexler et al., Lithium regulates adult hippocampal progenitor development through canonical Wnt pathway activation. Mol Psychiatry. Mar. 2008;13(3):285-92. Epub Oct. 30, 2007. [cited by applicant]
Woodgett, Physiological roles of glycogen synthase kinase-3: potential as a therapeutic target for diabetes and other disorders. Curr Drug Targets Immune Endocr Metabol Disord. Dec. 2003;3(4):281-90. Review. [cited by applicant]
Zhao et al., A high-throughput screen for Wnt/β-catenin signaling pathway modulators in human iPSC-derived neural progenitors. J Biomol Screen. Oct. 2012;17(9):1252-63. Epub Aug. 24, 2012. [cited by applicant]
Zhou et al., Forebrain overexpression of CK1delta leads to down-regulation of dopamine receptors and altered locomotor activity reminiscent of ADHD. Proc Natl Acad Sci U S A. Mar. 2, 2010;107(9):4401-6. doi: 10.1073/pna… [cited by applicant]
Invitation to Pay Additional Fees for Application No. PCT/US2023/076922, mailed Jan. 11, 2024. [cited by applicant]
International Search Report and Written Opinion for Application No. PCT/US2023/076922, mailed Apr. 4, 2024. [cited by applicant]
International Search Report and Written Opinion for Application No. PCT/US2024/033922, mailed Sep. 17, 2024. [cited by applicant]
Avraham et al., Glycogen synthase kinase 3beta modulates synphilin-1 ubiquitylation and cellular inclusion formation by SIAH: implications for proteasomal function and Lewy body formation. J Biol Chem. Dec. 30, 2005;280… [cited by applicant]
Beurel et al., Glycogen synthase kinase-3 (GSK3): regulation, actions, and diseases. Pharmacol Ther. Author manuscript; available in PMC: Apr. 1, 2016. Published in final edited form as: Pharmacol Ther. Nov. 27, 2014;0:… [cited by applicant]
Caracci et al., Synaptic Wnt/GSK3B Signaling Hub in Autism. Neural Plasticity. 2016; 2016:1-10. https://doi.org/10.1155/2016/9603751. [cited by applicant]
Carmichael et al., Glycogen synthase kinase-3beta inhibitors prevent cellular polyglutamine toxicity caused by the Huntington's disease mutation. J Biol Chem. Sep. 13, 2002;277(37):33791- 8. doi: 10.1074/jbc.M204861200.… [cited by applicant]
Carter et al., Specific glycogen synthase kinase-3 inhibition reduces neuroendocrine markers and suppresses neuroblastoma cell growth. Cancer Biol Ther. May 2014;15(5):510-5. doi: 10.4161/cbt.28015. Epub Feb. 12, 2014. [cited by applicant]
Chen et al., Identification of a Maleimide-Based Glycogen Synthase Kinase-3 (GSK-3) Inhibitor, BIP-135, that Prolongs the Median Survival Time of Δ7 SMA KO Mouse Model of Spinal Muscular Atrophy. ACS Chem Neurosci. Jan.… [cited by applicant]
Duka et al., Alpha-Synuclein contributes to GSK-3beta-catalyzed Tau phosphorylation in Parkinson's disease models. FASEB J. Sep. 2009;23(9):2820-30. doi: 10.1096/fj.08-120410. Epub Apr. 15, 2009. [cited by applicant]
Gaisina et al., From a Natural Product Lead to the Identification of Potent and Selective Benzofuran-3-yl-(indol-3-yl)maleimides as Glycogen Synthase Kinase 3β Inhibitors that Suppress Proliferation and Survival of Panc… [cited by applicant]
Giese, GSK-3: A Key Player in Neurodegeneration and Memory. IUBMB Life. May 2009;61(5):516-21. doi: 10.1002/iub.187. [cited by applicant]
Horig et al., From bench to clinic and back: Perspective on the 1st IQPC Translational Research conference. J Transl Med. Dec. 20, 2004;2(1):44. doi: 10.1186/1479-5876-2-44. [cited by applicant]
Jope et al., Glycogen synthase kinase-3 (GSK3) in psychiatric diseases and therapeutic interventions. Curr Drug Targets. Nov. 2006;7(11):1421-34. doi: 10.2174/1389450110607011421. [cited by applicant]
Koh et al., Brief Review of the Role of Glycogen Synthase Kinase-3β in Amyotrophic Lateral Sclerosis. Neurol Res Int. 2011:2011:205761. doi: 10.1155/2011/205761. Epub Mar. 20, 2011. [cited by applicant]
Kramer et al., Small-Molecule Inhibitors of GSK-3: Structural Insights and Their Application to Alzheimer's Disease Models. Int J Alzheimers Dis. 2012;2012:381029. doi: 10.1155/2012/381029. Epub Jul. 22, 2012. [cited by applicant]
Lee et al., Lovastatin modulates glycogen synthase kinase-3β pathway and inhibits mossy fiber sprouting after pilocarpine-induced status epilepticus. PLoS One. 2012;7(6):e38789. doi: 10.1371/journal.pone.0038789. Epub J… [cited by applicant]
Li et al., Regulation of glycogen synthase kinase-3 during bipolar mania treatment. Bipolar Disord. Author manuscript; available in PMC: Nov. 1, 2011. Published in final edited form as: Bipolar Disord. Nov. 2010;12(7):7… [cited by applicant]
Luo, Lithium-mediated protection against ethanol neurotoxicity. Front Neurosci. Jun. 28, 2010:4:41. doi: 10.3389/fnins.2010.00041. eCollection 2010. [cited by applicant]
Magedov et al., Structural simplification of bioactive natural products with multicomponent synthesis: dihydropyridopyrazole analogues of podophyllotoxin. Bioorg Med Chem Lett. Mar. 1, 2007;17(5):1381-5. doi: 10.1016/j.… [cited by applicant]
Maixner et al., The Role of Glycogen Synthase Kinase 3 Beta in Neuroinflammation and Pain. J Pharm Pharmacol (Los Angel). Author manuscript; available in PMC: Oct. 10, 2014. Published in final edited form as: J Pharm Ph… [cited by applicant]
Meanwell, Synopsis of some recent tactical application of bioisosteres in drug design. J Med Chem. Apr. 28, 2011;54(8):2529-91. doi: 10.1021/jm1013693. Epub Mar. 17, 2011. [cited by applicant]
Mo et al., CXCR4/CXCL12 mediate autocrine cell- cycle progression in NF1-associated malignant peripheral nerve sheath tumors. Cell. Feb. 28, 2013;152(5):1077-90. doi: 10.1016/j.cell.2013.01.053. Epub Feb. 21, 2013. [cited by applicant]
No Author Listed, PubChem SID 131724970. Submitted: Jan. 24, 2012. Last updated: May 31, 2019. 4 pages. [cited by applicant]
Roca et al., Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2016-2019). Expert Opin Ther Pat. Nov. 2020;30(11):863-872. doi: 10.1080/13543776.2020.1815706. Epub Sep. 14, 2020. [cited by applicant]
Sahin et al., Regulation of GSK-3 Activity as A Shared Mechanism in Psychiatric Disorders. Bulletin of Clinical Psychopharmacology. 2014; 24(1): 97-108. DOI: 10.5455/bcp.20140317063255. [cited by applicant]
Schafer et al., Failure is an option: learning from unsuccessful proof-of-concept trials. Drug Discov Today. Nov. 2008;13(21-22):913-6. doi: 10.1016/j.drudis.2008.03.026. Epub Jun. 17, 2008. [cited by applicant]
Schaffer et al., Association of GSK3B With Alzheimer Disease and Frontotemporal Dementia. Arch Neurol. Author manuscript; available in PMC: Mar. 17, 2010. Published in final edited form as: Arch Neurol. Oct. 2008;65(10)… [cited by applicant]
Shakoori et al., Inhibition of GSK-3 beta activity attenuates proliferation of human colon cancer cells in rodents. Cancer Sci. Sep. 2007;98(9):1388-93. doi: 10.1111/j.1349-7006.2007.00545.x. Epub Jul. 19, 2007. [cited by applicant]
Takashima, GSK-3 is essential in the pathogenesis of Alzheimer's disease. J Alzheimers Dis. 2006;9(3 Suppl):309-17. doi: 10.3233/jad-2006-9s335. [cited by applicant]
Wu et al., Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation. Cell Rep. Mar. 1, 2016;14(8):1979-90. doi: 10.1016/j.celrep.2016.01.074. Epub Feb. 18, 2016. [cited by applicant]
International Preliminary Report on Patentability for Application No. PCT/US2023/076922, mailed Apr. 24, 2025. [cited by applicant]
Ohuchi et al., Established Stem Cell Model of Spinal Muscular Atrophy Is Applicable in the Evaluation of the Efficacy of Thyrotropin-Releasing Hormone Analog. Stem Cells Transl Med. Feb. 2016;5(2):152-63. doi: 10.5966/s… [cited by applicant]
Takadera et al., Glycogen synthase kinase-3 inhibitors prevent caspase-dependent apoptosis induced by ethanol in cultured rat cortical neurons. Eur J Pharmacol. Sep. 24, 2004;499(3):239-45. doi: 10.1016/j.ejphar.2004.07… [cited by applicant]